The Top 5 Biosimilar Articles for the Week of July 28

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

July 27th 2025

By Skylar Jeremias

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization in this engaging podcast episode.

The Top 5 Biosimilar Articles for the Week of July 21

July 25th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of July 21, 2025.

Bevacizumab Biosimilar Fills Gap for Retinal Disease With Encouraging Safety Data

July 23rd 2025

By Skylar Jeremias

Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.

Data Show Comparable Efficacy, Added Cost Benefit With Adalimumab Biosimilar vs Humira

July 22nd 2025

By Skylar Jeremias

Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates.

Slow Biosimilar Uptake in Latin America Signals Missed Opportunities for Patient Access, Cost Savings

July 21st 2025

By Skylar Jeremias

Biosimilars promise cost savings and improved patient access in Latin America, yet face significant regulatory and educational barriers hindering their uptake.

The Top 5 Biosimilar Articles for the Week of July 14

July 18th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of July 14, 2025.

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap

July 16th 2025

By Skylar Jeremias

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

FDA Approves Kirsty as First Interchangeable Insulin Aspart Biosimilar

July 15th 2025

By Skylar Jeremias

The FDA has approved Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.

White Paper Offers Tips for Sustaining Biosimilar Progress, Avoiding a Market Void

July 15th 2025

By Skylar Jeremias

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced education to ensure market sustainability.

BioRationality: How the FDA Can Bypass Congress to Change Biosimilar Guidance

July 14th 2025

By Sarfaraz K. Niazi, PhD